Skip to main content

Sensus Healthcare Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

SRTS$3.30+3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended
September 30,
(in thousands) · 2024 · 2023
Cash flows from operating activities
Net income (loss)$5,101$(3,725)
Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities:
Credit loss expense1237
Depreciation and amortization154216
Gain on sale of property and equipment-(42)
Amortization of right-of-use asset144139
Provision for product warranties81325
Stock-based compensation201276
Deferred income taxes(57)(1,428)
Changes in operating assets:
Accounts receivable(6,439)10,409
Inventories(859)(9,818)
Prepaid inventory1,2632,315
Other current assets(708)(680)
Other noncurrent assets214187
Changes in operating liabilities:
Accounts payable and accrued expenses1,180(1,522)
Operating lease liability(132)(152)
Income tax payable(37)(890)
Deferred revenue35(44)
Product warranties(268)(386)
Net cash used in operating activities(4)(4,813)
Cash flows from investing activities
Acquisition of property and equipment(573)(229)
Proceeds from sale of assets-42
Net cash used in investing activities(573)(187)
Cash flows from financing activities
Repurchase of common stock-(27)
Withholding taxes on stock-based compensation(47)(52)
Exercise of stock options3446
Net cash used in financing activities(13)(33)
Net decrease in cash and cash equivalents(590)(5,033)
Cash and cash equivalents – beginning of period23,14825,520
Cash and cash equivalents – end of period$22,558$20,487
Supplemental disclosure of cash flow information:
Interest paid$-$-
Income tax paid$2,474$1,440
Supplemental schedule of noncash investing and financing transactions:
Transfer of inventory to property and equipment$752$117
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.